We are proud to participate in a newly established program training the cardiovascular scientists of tomorrow: The English-language MSc Medical Sciences – Cardiovascular Research is a 1-year program, combining taught (first term) and project research (second term) content. It is dedicated to more…
Epigenetic modulators have been proposed as promising new drug targets to treat adverse remodeling in heart failure. Here, we evaluated the potential of 4 epigenetic drugs, including the pan-BRD (bromodomain-containing protein) inhibitor bromosporine, the BET (bromodomain and extraterminal) inhibitor JQ1, more…
Mineralocorticoid receptor antagonists (MRAs) are highly effective therapies for cardiovascular and renal disease. However, the widespread clinical use of currently available MRAs in cardiorenal medicine is hampered by an increased risk of hyperkalemia. The mineralocorticoid receptor (MR) is a nuclear more…
